ViiV Healthcare

135 articles about ViiV Healthcare

• GlaxoSmithKline-Pfizer Inc.'s ViiV Healthcare Wins Approval For HIV Combo Drug

  8/25/2014

• ViiV Healthcare: HIV Combo Therapy Candidate Fails Phase 3

  7/23/2014

• GlaxoSmithKline's ViiV Healthcare Joins Johnson & Johnson's Janssen Research & Development To Develop Single-Pill HIV Drug

  6/12/2014

• GlaxoSmithKline's ViiV Healthcare Unit Adds New HIV Drug To AIDS Patent Pool

  4/2/2014

• ViiV Healthcare Release: Tivicay® (dolutegravir) Receives Positive CHMP Opinion In Europe For The Treatment Of HIV

  11/22/2013

• ViiV Healthcare Presents Positive Data From Phase 3b/4 Study of Dolutegravir Vs Darunavir in Treatment-Naive Adults With HIV-1

  9/13/2013

• GlaxoSmithKline Says No Plan for ViiV Healthcare Spinoff "at the Moment"

  1/10/2013

• ViiV Healthcare Says Phase III Data From VIKING-3 Dolutegravir Study Encouraging

  11/14/2012

• Shionogi, Inc.-ViiV Healthcare to File HIV Drug dolutegravir for Approval

  10/4/2012

• ViiV Healthcare Expands Commitment to Addressing Gaps in Paediatric HIV Research, Care and Treatment

  7/18/2012

• Siemens Healthcare Diagnostics Forms New Companion Diagnostics Partnerships with ViiV Healthcare and Tocagen Inc.

  2/8/2012

• ViiV Healthcare's Positive Action for Children Fund Announces 16 New Grantees for the Year 2011/2012

  10/13/2011

• ViiV Healthcare Starts Phase III Clinical Programme of Celsentri/Selzentry® (maraviroc) Versus Truvada® (tenofovir + FTC), in Combination With a Protease Inhibitor in People Living With HIV

  10/11/2011

• ViiV Healthcare, Pfizer Inc., GlaxoSmithKline JV Denies Changing Discounts to AIDS Drugs

  7/22/2011

• Idenix Pharmaceuticals, Inc. Announces $20 Million Milestone Payment From ViiV Healthcare for Initiation of Phase IIb Trial of '761

  11/23/2010